Tue, Sep 23, 2014, 1:17 PM EDT - U.S. Markets close in 2 hrs 43 mins


% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

deskjet325 5 posts  |  Last Activity: Sep 15, 2014 9:24 PM Member since: Mar 10, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • deskjet325 by deskjet325 Sep 15, 2014 9:24 PM Flag

    TG Therapeutics announces special protocol assessment agreement with the FDA for its first phase 3 clinical trial of TG-1101 in combination with imbruvica for patients with previously treated chronic lymphocytic leukemia (TGTX) :

    Co announced that it has reached an agreement with the FDA regarding a Special Protocol Assessment on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101, its glycoengineered anti-CD20 monoclonal antibody, in combination with Imbruvica for the treatment of Chronic Lymphocytic Leukemia in patients with high risk cytogenetics.

  • Reply to

    Imbruvica(tm) (ibrutinib) Market

    by hundleyrandy Sep 2, 2014 10:02 PM
    deskjet325 deskjet325 Sep 3, 2014 6:22 AM Flag

    lets not forget JNJ's other responsibility as far as expenses go..

  • brutinib (formerly PCI-32765) is a specific, irreversible, and potent inhibitor of Burton’s tyrosine kinase (BTK) developed for the treatment of several forms of blood cancer. It is now an FDA-approved drug marketed under the name ImbruvicaTM (Pharmacyclics, Inc.) and successfully used as an orally administered second-line drug in the treatment of mantle cell lymphoma. Since BTK is predominantly expressed in hematopoietic cells, the sensitivity of solid tumor cells to Ibrutinib has not been analyzed. In this study, we determined the effect of Ibrutinib on breast cancer cells. We demonstrate that Ibrutinib efficiently reduces the phosphorylation of the receptor tyrosine kinases ErbB1, ErbB2 and ErbB3, thereby suppressing AKT and MAPK signaling in ErbB2-positive (ErbB2+) breast cancer cell lines. Treatment with Ibrutinib significantly reduced the viability of ErbB2+ cell lines with IC50 values at nanomolar concentrations, suggesting therapeutic potential of Ibrutinib in breast cancer. Combined treatment with Ibrutinib and the dual PI3K/mTOR inhibitor BEZ235 synergistically reduces cell viability of ErbB2+ breast cancer cells. Combination indices below 0.25 at 50 % inhibition of cell viability were determined by the Chou-Talalay method. Therefore, the combination of Ibrutinib and canonical PI3K pathway inhibitors could be a new and effective approach in the treatment of breast cancer with activated ErbB receptors. Ibrutinib could thus become a valuable component of targeted therapy in aggressive ErbB2+ breast cancer.

  • deskjet325 by deskjet325 Jul 30, 2014 6:46 AM Flag

    When will this company ..if you want to call it that ..have some real news???

  • Reply to

    any old timers here?

    by lesssee123 Jul 3, 2014 11:52 AM
    deskjet325 deskjet325 Jul 12, 2014 7:31 PM Flag

    I 2nd that ..??????

119.4133-0.5267(-0.44%)1:17 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.